Evidence map›Paper›PMID 33974173›Full record

ArticleThe AAPS journal2021

Structure-Based SAR in the Design of Selective or Bifunctional Nociceptin (NOP) Receptor Agonists.

Michael E Meyer, Arpit Doshi, Dennis Yasuda, Nurulain T Zaveri

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Michael E MeyerAstraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, California, 94043, USA.
Arpit DoshiAstraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, California, 94043, USA.
Dennis YasudaAstraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, California, 94043, USA.
Nurulain T ZaveriAstraea Therapeutics, LLC, 320 Logue Avenue, Mountain View, California, 94043, USA. nurulain@astraeatherapeutics.com.
Astraea Therapeutics (United States) · US

Funding

Discovery of Bifunctional NOP/Opioid Receptor Ligands for Drug Abuse TherapyR01DA027811 · NIDA · ASTRAEA THERAPEUTICS, LLC · PI ZAVERI, NURULAIN T · 2009 to 2014
$3.4M
A NOVEL APPROACH FOR PAIN TREATMENT WITHOUT OPIOID LIABILITIESR44DA042465 · NIDA · ASTRAEA THERAPEUTICS, LLC · PI ZAVERI, NURULAIN T · 2016 to 2017
$1.5M
Development of Novel Therapies for Levodopa-induced Dyskinesia in Parkinson's DisR43NS070664 · NINDS · ASTRAEA THERAPEUTICS, LLC · PI ZAVERI, NURULAIN T · 2010 to 2010
$241k
NICHD NIH HHS HHSN275201300005CNICHD NIH HHS HHSN275201500005CNIDA NIH HHS R01 DA027811NIDA NIH HHS R44 DA042465NINDS NIH HHS R43 NS070664
6 · The paper itself

Abstract

The nociceptin opioid receptor (NOP), the fourth member of the opioid receptor family, and its endogenous peptide ligand, nociceptin or orphanin FQ (N/OFQ), play a vital role in several central nervous system pathways regulating pain, reward, feeding, anxiety, motor control and learning/memory. Both selective NOP agonists as well as bifunctional agonists at the NOP and mu opioid receptor (MOP) have potential therapeutic applications in CNS disorders related to these processes. Using Surflex-Dock protocols, we conducted a computational structure-activity study of four scaffold classes of NOP ligands with varying NOP-MOP selectivity. By docking these compounds into the orthosteric binding sites within an active-state NOP homology model, and an active-state MOP crystal structure, the goal of this study was to use a structure-based drug design approach to modulate NOP affinity and NOP vs. MOP selectivity. We first docked four parent compounds (no side chain) to determine their binding interactions within the NOP and MOP binding pockets. Various polar sidechains were added to the heterocyclic A-pharmacophore to modulate NOP ligand affinity. The substitutions mainly contained a 1-2 carbon chain with a polar substituent such as an amine, alcohol, sulfamide, or guanidine. The SAR analysis is focused on the impact of structural changes in the sidechain, such as chain length, hydrogen bonding capability, and basic vs neutral functional groups on binding affinity and selectivity at both NOP and MOP receptors. This study highlights structural modifications that can be leveraged to rationally design both selective NOP and bifunctional NOP-MOP agonists with different ratios of functional efficacy.

Indexed as

Drug DesignBinding SitesLigandsMolecular Docking SimulationMolecular StructureNociceptin ReceptorReceptors, OpioidReceptors, Opioid, muSequence Homology, Amino AcidStructure-Activity RelationshipLigandsNociceptin ReceptorReceptors, OpioidReceptors, Opioid, muactive-statehomology modelnociceptin receptorpharmacophoreselective or bifunctional nociceptin agoniststructure-based drug design

Identifiers

PMID33974173
OpenAlexW3160119161

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.